Antengene Corporation Ltd banner

Antengene Corporation Ltd
HKEX:6996

Watchlist Manager
Antengene Corporation Ltd Logo
Antengene Corporation Ltd
HKEX:6996
Watchlist
Price: 5.32 HKD -0.75% Market Closed
Market Cap: HK$3.6B

Antengene Corporation Ltd
Investor Relations

Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.

Show more
Loading
6996
Hang Seng (Hong Kong)
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Jay Mei M.D., Ph.D.
Founder, Chairman & CEO
No Bio Available
Mr. Donald Andrew Lung J.D., M.B.A.
CFO & Executive Director
No Bio Available
Mr. Eitan Liu M.Sc.
Chief Operating Officer
No Bio Available
Ms. Shimin Sun M.D., M.P.H.
Corporate VP and Head of Clinical Enabling Functions & Operational Excellence
No Bio Available
Mr. Thomas Karalis B.Sc.
Corporate VP & Head of Asia Pacific Region
No Bio Available
Dr. Dirk Hoenemann
VP and Head of Medical Affairs for APAC & Early Clinical Development
No Bio Available
Dr. Xiaojing Zhang
Chief Medical Officer
No Bio Available
Mr. Wai Chiu Wong FCS
Joint Company Secretary
No Bio Available

Contacts

Address
SHANGHAI
Shanghai
Suites 1206-1209, Block B, Zhongshan SOHO Plaza, 1065 West Zhongshan Road, Changning District
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett